Company Overview of F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd. provides in-vitro diagnostics and drugs for cancer and transplantation. The company specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. The company also researches, develops, and produces molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostic...
Founded in 1896
Key Executives for F. Hoffmann-La Roche Ltd
Chief Executive Officer of Roche Group
Compensation as of Fiscal Year 2016.
F. Hoffmann-La Roche Ltd Key Developments
F. Hoffmann-La Roche Ltd to Report Q3, 2016 Sales/Trading Statement Results on Oct 20, 2016
Oct 20 16
F. Hoffmann-La Roche Ltd announced that they will report Q3, 2016 sales/trading statement results on Oct 20, 2016
F. Hoffmann-La Roche Ltd. Reports Earnings Results for the Six Months Ended June 30, 2016
Jul 25 16
F. Hoffmann-La Roche Ltd. reported earnings results for the six months ended June 30, 2016. For the six months, the company reported net income attributable to shareholders was CHF 5.38 billion, or CHF 6.24 per diluted share, compared to CHF 5.15 billion, or CHF 5.98 per diluted share, for the same period a year ago. Sales were CHF 25.02 billion, compared to CHF 23.58 billion for the same period a year ago. Operating profit was CHF 8.14 billion, compared to CHF 7.71 billion for the same period a year ago. Profit before taxes was CHF 7.52 billion, compared to CHF 7.08 billion for the same period a year ago.
F. Hoffmann-La Roche Ltd Presents at 16th Annual Biotech in Europe Forum, Sep-27-2016 through Sep-28-2016
Jun 17 16
F. Hoffmann-La Roche Ltd Presents at 16th Annual Biotech in Europe Forum, Sep-27-2016 through Sep-28-2016. Venue: MCH Messe Schweiz (Basel) AG, Messepl. 21, CH-4058 Basel, Switzerland. Presentation Date & Speakers: Sep-27-2016, Maria Bobadilla, William Pao, Global Head of the Oncology Discovery and Translational Area (DTA), Roche Pharmaceutical Research & Early Development (pRED).
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|